Regulating Pharmaceutical Prices in the European Union

Csizmazia, Roland Attila (2013): Regulating Pharmaceutical Prices in the European Union. Published in: International Journal of Business Knowledge and Innovation in Practice , Vol. 1, No. 1 (15 December 2013): pp. 8-20.

Abstract

This case study aims to provide a better understanding of the necessity for regulation in the market for pharmaceuticals and to reveal the impacts of parallel trades in the European Union and how they may affect markets in the future. The pharmaceutical industry up to now has largely been regulated. Although the EU is a single market, it still has variable prices for pharmaceuticals. Consequently, the price gap and other EU-specific factors have created a great environment for parallel trades. The author has confined this study to the price regulations inside the EU before the enlargement in 2004.

• Item Type: MPRA Paper
• Language: English
• Keywords: Regulation, pharmaceutical market, European Union, parallel trade
• Subjects: D - Microeconomics > D4 - Market Structure, Pricing, and Design > D40 - General

References

Balfour F., Matlack C., Barrett A., Capell K., Roberts, D., Wheatley, J., Symonds, C. W., Magnusson P., Brady D., (2005) Fakes!, Businessweek, 6 February, http://www.businessweek.com/stories/2005-02-06/fakes, accessed 22 October 2013

Danzon, M. P. and Towse, A. (2003) Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents. International Journal of Health Care Finance and Economics 3 (3): 183-205.

EAASM (2007) European Patient Safety and Parallel Pharmaceutical Trade – a potential public health disaster? European Alliance for Access to Safe Medicines and Dr Jonathan Harper, Vol. 1, No. 1, 19. http://www.europeanbraincouncil.org/pdfs/Publications_/Harper%20Report%20Summary.pdf, accessed 22 October 2013.

Ess, M. S., Schneeweiss, S. and Szucs, T. D. (2003) European Healthcare Policies for Controlling Drug Expenditure. PharmacoEconomics 21 (2): 89-103.

EU (2001) Directive 2001/83/EC of The European Parliament and of The Council . Official Journal of the European Communities 44/L311: 67-119.

Haigh, J. (2002) Parallel trade – the number one concern in Europe. IM Health Report, 30 October, http://lists.essential.org/pipermail/ip-health/2004-February/005992.html, accessed 22 October 2013.

Jia, W. and Zhang, L. (2005) Challenges and Opportunities in the Chinese Herbal Drug Industry. In: Zhang, L., Demain, A. L. (eds.) Natural Products: Drug Discovery and Therapeutic Medicine. Totowa and New Jersey: Humana Press, pp. 229-250.

Kanavos, P., Costa-i-Font, J., Merkur, S., Gemmill, M. (2004) The economic impact of pharmaceutical parallel trade in European union member states: a stakeholder analysis. LSE Special Research Paper: p. 147.

Maynard A. and Bloor K. (2003) Dilemmas In Regulation Of The Market For Pharmaceuticals. Health Affairs 22 (3): 31-41, doi: 10.1377/hlthaff.22.3.31

Mossialos, E., Mrazek, M.,Walley, T. (2004) Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Berkshire: Open University Press.

Olivieri, N. F. (2003) Patients’ health or company profits? The commercialisation of academic research. Science and Engineering Ethics 9 (1): 29-41.

Palley, T. (2005) From Keynesianism to Neoliberalism: Shifting Paradigms in Economics. In: Saad-Filho, A. and Johnson, D. (eds.) Neoliberalism a Critical Reader. London: Pluto Press, pp. 20-29.

Reekie D. (1997) Regulations Without a Cause. In: Green D., Brown P., Burstall M., Mossialos E., Redwood H., Reekie W. D. (eds.) Should Phatmaceutical Ptices be Regulated? The Strengths and Weaknesses of the Pharmaceutical Price Regulation Scheme, London: Institute of Economic Affairs.

Wearing, A., Kirby, I., Van Kerckhove, M., and Vodra, W. Arnold & Porter LLP (2004) Parallel Trade in the EU and US pharmaceutical markets. In: Life Sciences 2004/05. London: Practical Law Company Limited, pp. 117-124.